Contineum (CTNM) awards non-employee director 19,000 stock options

Rhea-AI Filing Summary

Contineum Therapeutics director Diego Miralles received a new stock option grant as part of standard board compensation. He was awarded options over 19,000 shares of Class A common stock at an exercise price of $14.19 per share under the company’s 2024 Equity Incentive Plan.

The grant was made pursuant to Contineum’s Non-Employee Director Compensation Program, which provides an automatic option for 19,000 shares after each regular annual meeting for continuing non-employee directors. The options vest in full on the earlier of June 26, 2027, or the next regular annual stockholder meeting, subject to his continuous service, and expire on June 25, 2036. Following this grant, Miralles holds 19,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Miralles Gines Diego

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 19,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 19,000 shares Exercise price: $14.19 per share Expiration date: June 25, 2036 +2 more

5 metrics

Option grant size 19,000 shares Stock option award to director Diego Miralles

Exercise price $14.19 per share Strike price for newly granted options

Expiration date June 25, 2036 Option term end for this grant

Total options held after grant 19,000 options Direct holdings following transaction

Vesting date trigger Earlier of June 26, 2027 or next annual meeting Full vesting condition for the option grant

Key Terms

2024 Equity Incentive Plan, Non-Employee Director Compensation Program, stock option, Class A Common Stock

4 terms

2024 Equity Incentive Plan financial

"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program"

Non-Employee Director Compensation Program financial

"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting"

stock option financial

"will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Class A Common Stock financial

"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 05:47 PM Accepted by SEC EDGAR 06/26/2026 - 05:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miralles Gines Diego

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.19	06/26/2026		A		19,000		(1)	06/25/2036	Class A Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Contineum Therapeutics (CTNM) director Diego Miralles receive in this Form 4 filing?

Diego Miralles received a grant of stock options for 19,000 shares of Contineum Therapeutics Class A common stock. The award is part of the company’s standard non-employee director compensation program under its 2024 Equity Incentive Plan.

What is the exercise price and term of Diego Miralles’ new Contineum (CTNM) stock options?

The new stock options have an exercise price of $14.19 per share and expire on June 25, 2036. This gives Miralles the right to buy 19,000 shares at that price anytime before the expiration date, once the options are vested.

When do Diego Miralles’ Contineum Therapeutics (CTNM) stock options vest?

The options vest in full on the earlier of June 26, 2027, or the next regular annual meeting of stockholders. Vesting is conditioned on Miralles’ continuous service as a non-employee director on Contineum’s board through that vesting date.

Under which plan were the new Contineum (CTNM) stock options to Diego Miralles granted?

The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan. They were issued pursuant to the company’s Non-Employee Director Compensation Program, which provides automatic annual stock option grants to continuing non-employee board members.

How many Contineum Therapeutics (CTNM) stock options does Diego Miralles hold after this transaction?

After this transaction, Miralles holds 19,000 stock options directly. This amount matches the newly granted options, indicating this award represents his full reported option position in this specific Form 4 filing excerpt.